WiCON | Pharma China (Web Edition)

ONLINE ENQUIRY

WiCON International Group
21 Bridge Street
Metuchen, NJ 08840, USA
Tel/Fax: +1 801-751-5728
info@pharmachinaonline.com

Affiliated Companies
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com

BJ Jicai PharmTech
Oriental Kenzo Plaza
Beijing, China
Tel: +86 10 84476010
info@pharmachinaonline.com

MNCs Rethink China Strategy as New Opportunities Emerge in Special Zones Chief Editor James Shen offers his monthly review of the Chinese healthcare sector with emphasis on MNC repositioning in China, healthcare reform blueprint laid out recen...
(4/8/2021)

PhIRDA/RDPAC: Fostering China Pharmaceutical I... (4/19/2021)

How China Passed Up a Vaccine Opportunity and ... (4/15/2021)

FiercePharma: BeiGene Details Novartis-partner... (4/12/2021)

PharmaDJ's China Biotech Fundraising Tracker: ... (4/12/2021)

MNCs Rethink China Strategy as New Opportuniti... (4/8/2021)

China's 14th Five-Year Plan (2021-2025): Signp... (4/8/2021)

Shanghai Henlius Biotech Maps Out Its Biosimil... (4/7/2021)

A Stronger Protection of Trade Secret in China (4/6/2021)

PharmaDJ's China Licensing Deals Tracker: Feb ... (4/5/2021)

Patent Term Extension and Patent Linkage for P... (4/1/2021)

PharmaDJ: New Regulations for Post-Market Drug... (3/31/2021)

China's Healthcare System: Addressing Capacity... (3/31/2021)

Cansino to Initiate Trials of Its Inhal... (4/19/2021) A Share-Listed Chinese MedPharm Cos Repo... (4/19/2021) Recent Executive Moves (4/16/2021) NHC Approves Setup of National Medical C... (4/16/2021) Chinese Blood Products Market Continued ... (4/16/2021) Kintor Granted Chinese Clinial Trial App... (4/16/2021) Sinopharm to Inject $4.6 bln Vaccine Ass... (4/16/2021) (Free) Biogen's Tecfidera Approved in China for... (4/16/2021) PhIIC: Urban Chinese Hospital Drug Sales... (4/16/2021) State Council Calls for Liberalization o... (4/16/2021) Numerous Local Champions and MNCs Among ... (4/15/2021) China Issues the 2021 Work Highlights of... (4/15/2021) Latest Update on the Upcoming 5th Round ... (4/15/2021) CDE Issues the Guidance Principles on Re... (4/15/2021) CDE Publicizes the List of Reference For... (4/15/2021) NMPA Issues the Principles of Classifica... (4/15/2021) Hugel Expands China Presence with New Su... (4/15/2021) Lonza to Make Junshi Biosciences Antibod... (4/15/2021)

PhIIC: Urban Chinese Hospital Drug Sales Down 13% in 20... Chinese Blood Products Market Continued to Grow in 2020 Performance Review of Drug Products Included in the NRD... NH's DB6: Chinese Consumer Healthcare Market Review 201... NH's DB6: Top Ten Chinese OTC Brands in 2020

A Share-Listed Chinese MedPharm Cos Report Performance ... Biogen's Tecfidera Approved in China for Relapsing Mult... Sinopharm to Inject $4.6 bln Vaccine Assets into Unit T... Kintor and Visum Announced Strategic Partnership to Exp... Lonza to Make Junshi Biosciences Antibody at China Faci...

State Council Calls for Liberalization of Online Prescr... NMPA Issues the Principles of Classification and Defini... CDE Publicizes the List of Reference Formulations for G... CDE Issues the Guidance Principles on Real World Data U... CDE Solicits Comments on the Technical Guidelines for C...

NHC Approves Setup of National Medical Centers for Infe... Latest Update on the Upcoming 5th Round of VBP China Issues the 2021 Work Highlights of the Healthy Ch... CAMS and PUMC Review Chinese Cancer Trends from 1990 to... CMJ: Changing Profiles of Cancer Burden Worldwide and i...

Numerous Local Champions and MNCs Among the 19 Pharma C... Chinese MOF Fines 19 Pharma Companies for Inflating Dru... SAMR Fines Yangtze River Pharma CNY 764M for Violation... CNIPA Invalidates Pfizer's Chinese Patent of Sutent (Su... Shanghai Passes Law to Facilitate Traditional Chinese M...

Teva CEO Talks About Risks in Excessive Reliance on Chi... Indian Pharma Firms Go Local Seeking to End Reliance on... India Probes Alleged API Dumping by Chinese Companies China Increases Prices of Key Drug Ingredients by Up To... U.S. Introduces A 'Buy American First' Pharma Executive...

Cansino to Initiate Trials of Its Inhaled COVID-19 Vac... Kintor Granted Chinese Clinial Trial Approval of AR-PR... Simcere's Marketing Application for First-to-copy Ibrut... China Approves New COVID-19 Vaccine for Clinical Trials NMPA Accepts NDA for Ocumension's OT-401 (YUTIQ) on Rea...

BioAtla and BeiGene Revise Global Deal for Novel Condit... Pfizer to Absorb Mylan, Creating Global Generic Powerho... PhRMA Calls for Trade Deals That Force Countries to Pay... IQVIA: Global Pharma to Grow Slower in the Next Five Ye... Pfizer and GSK Announce JV to Create a Global Consumer ...

Recent Executive Moves Recent Executive Moves Recent Executive Moves Six Chinese Healthcare Billionaires in the Top 100 of H... Recent Executive Moves

U.S. Chamber Releases In-Depth Analysis of U.S.-China E... Upcoming Event: Plenareno Pharma Middle East Virtual Co... Live Podcast - VC & Impact Investing in China: Investin... 2020 Fall/Winter Promotion - Pharma China publications USTR Satisfied with China's Implementatin of Phase 1 US...

Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...

WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...

Pharma China on Twitter and Faceboo... WiCON Publishes the China Pharmaceu... WiCON Publishes the China Pharmaceu... WiCON to Hold Pharma China Annual F... WiCON Publishes the China Pharmaceu...